Please note: AABB reserves the right to make updates to this program.
Live Program Date: Thursday, April 23, 2020 - On-Demand Available
Master Program Number: 20EL-526 (see program format numbers below under Registration)
Educational Track: Technical/Clinical
Topic: Cellular Therapies
Intended Audience: Hospitals, Hospital Blood Banks, Medical Directors, Nurses, Physicians, Research Scientists, Residents/Fellows, Scientists, Students (MD, MT, SBB), Technologists
Teaching Level: Intermediate
Director/Moderator: Thomas Spitzer, MD, Director, Cellular Therapy and Transplantation Laboratory, Massachusetts General Hospital, Boston, MA
Speaker: Jonathan Hoggatt, PhD, Assistant Professor of Medicine, Harvard Medical School, Massachusetts General Hospital, Boston, MA
After participating in this educational activity, participants should be able to:
- Discuss historical approaches to hematopoietic stem cell mobilization.
- Describe the benefits and limitations of current stem cell mobilization approaches.
- Discuss a novel mobilization strategy involving the CXCR2 agonist GROβ and the CXCR4 agonist AMD3100.
This program will review the available approaches and the benefits and limitations of each to stem cell mobilization for hematopoietic cell transplantation, and discuss a promising novel, rapid strategy for stem cell mobilization utilizing the CXCR2 agonist GROβ and the CXCR4 agonist AMD3100.
AABB understands the value of learning together as a group but with COVID-19, bringing everyone together to share the experience in person may not be an option for your team. Given this, all participants in a group will be provided the ability to register as a single viewer (AABB will provide a promocode to registered group viewing coordinators to share with their team in advance of the live program). If you are a group interested in participating in this eCast, simply complete the Group Viewing registration form and AABB will provide detailed instructions to share with your team. For single viewers, the process has not changed.
| || ||
|Single Viewer: On-Demand||
|Group Viewing: On-Demand||
Continuing Education Credit
AABB designates both the live and on-demand version of this eCast each eligible for 1 continuing education credits/contact hours for General Participation, California Nurse, California Lab Personnel and Florida Lab Personnel. The number and type of credits awarded for this program (both live and on-demand) was determined by the program duration . Please note this program is not eligible for continuing medical education (CME) credit for physicians. For more information on each credit type please visit our
Continuing Education Credits webpage.
Disclosures for the planners of this event can be found
here. Disclosures for the program faculty are provided at the beginning of the program.
Dr. Jonathan Hoggatt is Assistant Professor of Medicine at Harvard Medical School and holds appointments in both the Center for Cancer Research and Center for Transplantation Sciences of Massachusetts General Hospital. Dr. Hoggatt is also a principal faculty member of the Harvard Stem Cell Institute and an affiliate faculty member of the Stem Cell and Regenerative Biology Department at Harvard University. Dr Hoggatt trained with Dr. Louis Pelus at Indiana University School of Medicine and did his post-doctoral training with Dr. David Scadden at Harvard University. Jon is an expert in stem cells and hematopoiesis and his research endeavors focus on translational science in hematopoietic stem cell transplantation. These studies have led to several clinical trials, licensed patents, and high-profile papers in
Nature, Nature Medicine, Cell, Blood, Leukemia and others. He holds several patents in novel stem cell therapies and is a co-founder of Magenta Therapeutics.